Skip to main content
Erschienen in: Tumor Biology 5/2014

01.05.2014 | Research Article

Impact of chemokines CCR532, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population

verfasst von: Vibha Singh, Praveen Kumar Jaiswal, Rohit Kapoor, Rakesh Kapoor, Rama Devi Mittal

Erschienen in: Tumor Biology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Chemokines are small inducible pro-inflammatory cytokines. In the present study, we tested association of chemokine single nucleotide polymorphisms (SNPs) viz., CCR532, CXCL12G801A and CXCR2C1208T genes in bladder cancer (BC) patients and normal healthy controls of north Indians. Genotyping of the above SNPs were done in 200 BC cases and 200 healthy controls, using RFLP and amplification refractory mutation system–polymerase chain reaction methodology. A significant association was found in CXCL12G801A with BC risk. In case of CXCL12G801A polymorphism, the heterozygous (GA) genotype showed significantly high risk (p < 0.001, odds ratio (OR) = 2.72), whereas A allele carrier (GA + AA) also showed risk with BC (p < 0.001, OR = 2.44). In CXCR2C1208T polymorphism, the variant genotype (TT) showed significant risk for BC (p = 0.028, OR = 1.58). The variant allele (T) of CXCR2C1208T polymorphism was found to be associated with BC risk (p = 0.003, OR = 1.29). Interestingly, smoking was also found to modulate 1.16-fold risks for BC in case of CXCR2C1208T, variant genotype (TT). Upon analyzing the gene–gene interaction between CXCR2C1208T and CXCL12G801A, the combination CT-GA showed 4-fold risk for BC (p = 0.009). Our results indicated that polymorphism in CXCR2C1208T and CXCL12G801A showed high risk for BC in north Indian population. However, CCR532 exhibited no association. Study with large sample size and diverse ethnicity are required to validate these observations.
Literatur
2.
Zurück zum Zitat Morgan D, Mahe C, Mayanja B, et al. Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. BMJ. 2002;324:193–6.CrossRefPubMedPubMedCentral Morgan D, Mahe C, Mayanja B, et al. Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. BMJ. 2002;324:193–6.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Horuk R. Molecular properties of the chemokines receptor family. Trends Pharmacol Sci. 1994;15:159–65.CrossRefPubMed Horuk R. Molecular properties of the chemokines receptor family. Trends Pharmacol Sci. 1994;15:159–65.CrossRefPubMed
4.
Zurück zum Zitat Ruster M, Sperschneider H, Funfstuck R, Stein G, Grone HJ. Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts. Clin Nephrol. 2004;61:30–9.CrossRefPubMed Ruster M, Sperschneider H, Funfstuck R, Stein G, Grone HJ. Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts. Clin Nephrol. 2004;61:30–9.CrossRefPubMed
5.
Zurück zum Zitat Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–77.CrossRefPubMed Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–77.CrossRefPubMed
6.
Zurück zum Zitat Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2:1240–3.CrossRefPubMed Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2:1240–3.CrossRefPubMed
7.
8.
Zurück zum Zitat Apostolakis S, Baritaki S, Kochiadakis GE, et al. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res. 2007;119:63–71.CrossRefPubMed Apostolakis S, Baritaki S, Kochiadakis GE, et al. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res. 2007;119:63–71.CrossRefPubMed
9.
Zurück zum Zitat Hirata H, Hinoda Y, Kikuno N, et al. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res. 2007;13:5056–62.CrossRefPubMed Hirata H, Hinoda Y, Kikuno N, et al. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res. 2007;13:5056–62.CrossRefPubMed
10.
Zurück zum Zitat de Oliveira CE, Cavassin GG, Perim Ade L, et al. Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients. J Clin Lab Anal. 2007;21:49–54.CrossRefPubMed de Oliveira CE, Cavassin GG, Perim Ade L, et al. Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients. J Clin Lab Anal. 2007;21:49–54.CrossRefPubMed
12.
Zurück zum Zitat Brant E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev. 2000;177:204–16.CrossRef Brant E, Ludwig A, Petersen F, Flad HD. Platelet-derived CXC chemokines: old players in new games. Immunol Rev. 2000;177:204–16.CrossRef
13.
Zurück zum Zitat Renzoni E, Lympany P, Sestini P. Distribution of novel polymorphisms of IL-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum. 2000;43:1633–40.CrossRefPubMed Renzoni E, Lympany P, Sestini P. Distribution of novel polymorphisms of IL-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum. 2000;43:1633–40.CrossRefPubMed
14.
Zurück zum Zitat Colombel M, Soloway M, Akaza H. Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol. 2008;7:618–26.CrossRef Colombel M, Soloway M, Akaza H. Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol. 2008;7:618–26.CrossRef
15.
16.
Zurück zum Zitat Singh R, Kapoor R, Srivastava A, et al. Impact of chemokine receptor CCR2 and CCR5 gene polymorphism on allograft outcome in north Indian renal transplant recipients. Scand J Immunol. 2009;69:51–6.CrossRefPubMed Singh R, Kapoor R, Srivastava A, et al. Impact of chemokine receptor CCR2 and CCR5 gene polymorphism on allograft outcome in north Indian renal transplant recipients. Scand J Immunol. 2009;69:51–6.CrossRefPubMed
17.
Zurück zum Zitat Manchanda PK, Singh R, Mittal RD. Cytokine (IL-10–1082 and -819) and chemokine receptor (CCR2 and CCR5) gene polymorphism in north Indian patients with end-stage renal disease. DNA Cell Biol. 2009;28:177–83.CrossRefPubMed Manchanda PK, Singh R, Mittal RD. Cytokine (IL-10–1082 and -819) and chemokine receptor (CCR2 and CCR5) gene polymorphism in north Indian patients with end-stage renal disease. DNA Cell Biol. 2009;28:177–83.CrossRefPubMed
18.
Zurück zum Zitat Ahluwalia TS, Khullar M, Ahuja M, et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy intype 2 diabetes among Asian Indians. PLoS One. 2009;4:51–68.CrossRef Ahluwalia TS, Khullar M, Ahuja M, et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy intype 2 diabetes among Asian Indians. PLoS One. 2009;4:51–68.CrossRef
19.
Zurück zum Zitat D’Angelo R, Crisafulli C, Rinaldi C, et al. CCR5Δ32 polymorphism associated with a slower rate disease progression in a cohort of RR-MS Sicilian patients. Mult Scler Int. 2011;2011:153–82. D’Angelo R, Crisafulli C, Rinaldi C, et al. CCR5Δ32 polymorphism associated with a slower rate disease progression in a cohort of RR-MS Sicilian patients. Mult Scler Int. 2011;2011:153–82.
20.
Zurück zum Zitat Srivastava A, Pandey SN, Choudhuri G, et al. CCR5 Delta32 polymorphism associated with gallbladder cancer susceptibility. Scand J Immunol. 2008;67:516–22.CrossRefPubMed Srivastava A, Pandey SN, Choudhuri G, et al. CCR5 Delta32 polymorphism associated with gallbladder cancer susceptibility. Scand J Immunol. 2008;67:516–22.CrossRefPubMed
21.
Zurück zum Zitat Kucukgergin C, Isman FK, Dasdemir S, et al. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene. 2012;10(511):7–11.CrossRef Kucukgergin C, Isman FK, Dasdemir S, et al. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene. 2012;10(511):7–11.CrossRef
22.
Zurück zum Zitat Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2–64I and CXCL12–3a in the development of sporadic breast cancer. J Med Genet. 2004;41:e59.CrossRefPubMedPubMedCentral Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2–64I and CXCL12–3a in the development of sporadic breast cancer. J Med Genet. 2004;41:e59.CrossRefPubMedPubMedCentral
23.
24.
Zurück zum Zitat Kruszyna L, Lianeri M, Rubis B, et al. CCL2–2518 A/G single nucleotide polymorphism as a risk factor for breast cancer. Mol Biol Rep. 2010;38:1263–7.CrossRefPubMed Kruszyna L, Lianeri M, Rubis B, et al. CCL2–2518 A/G single nucleotide polymorphism as a risk factor for breast cancer. Mol Biol Rep. 2010;38:1263–7.CrossRefPubMed
25.
Zurück zum Zitat Teng YH, Liu TH, Tseng HC, et al. Contribution of genetic polymorphisms of stromal cell-derived factor-1and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck. 2009;31:1282–8.CrossRefPubMed Teng YH, Liu TH, Tseng HC, et al. Contribution of genetic polymorphisms of stromal cell-derived factor-1and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. Head Neck. 2009;31:1282–8.CrossRefPubMed
26.
Zurück zum Zitat Dimberg J, Hugander A, Löfgren S, et al. Polymorphism and circulatinglevels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med. 2007;1:11–5. Dimberg J, Hugander A, Löfgren S, et al. Polymorphism and circulatinglevels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med. 2007;1:11–5.
27.
Zurück zum Zitat Ku FC, Tsai CR, Der Wang J, et al. Stromal-derived factor-1 gene variations in pediatric patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90:25–30.CrossRefPubMed Ku FC, Tsai CR, Der Wang J, et al. Stromal-derived factor-1 gene variations in pediatric patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90:25–30.CrossRefPubMed
28.
Zurück zum Zitat Vairaktaris E, Vylliotis A, Spyridonodou S, et al. DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer. Anticancer Res. 2008;28:271–5.PubMed Vairaktaris E, Vylliotis A, Spyridonodou S, et al. DNA polymorphism of stromal-derived factor-1 is associated with advanced stages of oral cancer. Anticancer Res. 2008;28:271–5.PubMed
29.
Zurück zum Zitat Lian LH, Kee BP, Ng HL, et al. Lack of association between RANTES-28, SDF-1 gene polymorphisms and systemic lupus erythematosus in the Malaysian population. Genet Mol Res. 2011;10:2841–50.CrossRefPubMed Lian LH, Kee BP, Ng HL, et al. Lack of association between RANTES-28, SDF-1 gene polymorphisms and systemic lupus erythematosus in the Malaysian population. Genet Mol Res. 2011;10:2841–50.CrossRefPubMed
30.
Zurück zum Zitat Işman FK, Kucukgergin C, Daşdemir S, et al. Association between SDF1-3′A or CXCR4 gene polymorphisms with predisposition toand clinicopathological characteristics of prostate cancer with or without metastases. Mol Biol Rep. 2012;39:1073–9.CrossRef Işman FK, Kucukgergin C, Daşdemir S, et al. Association between SDF1-3′A or CXCR4 gene polymorphisms with predisposition toand clinicopathological characteristics of prostate cancer with or without metastases. Mol Biol Rep. 2012;39:1073–9.CrossRef
31.
Zurück zum Zitat Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006;244:113–20.CrossRefPubMedPubMedCentral Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, et al. Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006;244:113–20.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Crazzolara R, Kreczy A, Mann G, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001;115:545–53.CrossRefPubMed Crazzolara R, Kreczy A, Mann G, et al. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001;115:545–53.CrossRefPubMed
33.
Zurück zum Zitat Javor J, Bucova M, Cervenova O, et al. Genetic variations of interleukin-8, CXCR1 and CXCR2 genes and risk of acutepyelonephritis in children. Int J Immunogenet. 2012;39:338–45.CrossRefPubMed Javor J, Bucova M, Cervenova O, et al. Genetic variations of interleukin-8, CXCR1 and CXCR2 genes and risk of acutepyelonephritis in children. Int J Immunogenet. 2012;39:338–45.CrossRefPubMed
34.
Zurück zum Zitat Duymaz-Tozkir J, Yilmaz V, Uyar FA, et al. Polymorphisms of the IL-8 and CXCR2 genes are not associated with Behçet’s disease. J Rheumatol. 2005;32:93–7.PubMed Duymaz-Tozkir J, Yilmaz V, Uyar FA, et al. Polymorphisms of the IL-8 and CXCR2 genes are not associated with Behçet’s disease. J Rheumatol. 2005;32:93–7.PubMed
35.
Zurück zum Zitat Snoussi K, Mahfoudh W, Bouaouina N, et al. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer. 2010;12:10–283. Snoussi K, Mahfoudh W, Bouaouina N, et al. Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer. 2010;12:10–283.
36.
Zurück zum Zitat Salim PH, Jobim M, Bredemeier M, et al. Combined effects of CXCL8 and CXCR2 gene polymorphisms on susceptibility to systemic sclerosis. Cytokine. 2012;60:473–7.CrossRefPubMed Salim PH, Jobim M, Bredemeier M, et al. Combined effects of CXCL8 and CXCR2 gene polymorphisms on susceptibility to systemic sclerosis. Cytokine. 2012;60:473–7.CrossRefPubMed
37.
Zurück zum Zitat Ben-Baruch A. Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 2003;5:31–6.CrossRefPubMed Ben-Baruch A. Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res. 2003;5:31–6.CrossRefPubMed
Metadaten
Titel
Impact of chemokines CCR5∆32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population
verfasst von
Vibha Singh
Praveen Kumar Jaiswal
Rohit Kapoor
Rakesh Kapoor
Rama Devi Mittal
Publikationsdatum
01.05.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1624-7

Weitere Artikel der Ausgabe 5/2014

Tumor Biology 5/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.